Loading…

Endothelial dysfunction in Graves' disease

Graves' disease (GD) is an organ-specific autoimmune thyroid disease, characterized by hyperthyroidism due to excessive production of thyroid hormone induced by thyrotropin receptor-specific stimulatory autoantibodies. In this study, we determined serum levels of the soluble forms of ICAM-1, VC...

Full description

Saved in:
Bibliographic Details
Published in:Advances in medical sciences 2013, Vol.58 (1), p.31-37
Main Authors: Popławska-Kita, A, Szelachowska, M, Modzelewska, A, Siewko, K, Dzięcioł, J, Klimiuk, PA, Górska, M
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c381t-3dd668b4ecb1dfb603399ea96e11271ad9047df187b7511e531c66913c8e823c3
cites cdi_FETCH-LOGICAL-c381t-3dd668b4ecb1dfb603399ea96e11271ad9047df187b7511e531c66913c8e823c3
container_end_page 37
container_issue 1
container_start_page 31
container_title Advances in medical sciences
container_volume 58
creator Popławska-Kita, A
Szelachowska, M
Modzelewska, A
Siewko, K
Dzięcioł, J
Klimiuk, PA
Górska, M
description Graves' disease (GD) is an organ-specific autoimmune thyroid disease, characterized by hyperthyroidism due to excessive production of thyroid hormone induced by thyrotropin receptor-specific stimulatory autoantibodies. In this study, we determined serum levels of the soluble forms of ICAM-1, VCAM-1, vWF, IL-6, IL-12, IL-18, fibrinogen and CRP in patients with subclinical (SH) and overt hyperthyroidism (OH) caused by GD to elucidate a possible role of those parameters as markers of endothelium dysfunction (ED). The study included 96 patients: 52 with GD and 44 euthyroid controls, divided into 3 groups according to their thyroid function tests: SH, OH and controls (CG). The values of IL-6, IL-12 and IL-18 were significantly higher in GD than in CG patients (p < 0.0001, p < 0.0001; p < 0.00001, respectively). Significant difference of sVCAM-1 values were found in the patients with GD compared to CG (p < 0.0001). Patients with GD had significantly higher levels of PAI-1 (p < 0.00001), vWF (p < 0.0001), fibrinogen (p < 0.0001) in comparison to CG. In patients with OH, we observed statistically higher values of fibrinogen compared to SH group (p < 0.05). There were no significant differences in serum concentration of other study parameters in patients with SH compared to the OH. ED occurs during subclinical and overt hyperthyroidism causing decreased fibrinolytic activity, hypercoagulability and increased levels of IL-6, Il-12 and IL-18. These results support the notion that serum cytokines could be used as a marker of GD activity. Results of this study support the opinion that GD might require treatment as early as in the phase of SH.
doi_str_mv 10.2478/v10039-012-0047-1
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1399933307</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1896112614601681</els_id><sourcerecordid>3369101961</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-3dd668b4ecb1dfb603399ea96e11271ad9047df187b7511e531c66913c8e823c3</originalsourceid><addsrcrecordid>eNp9kM9LwzAUx4Mobk7_AC8y8KAI0bykTRs8yZg_YOBFz6FNXjGja2fSDvbfm9npwYOnPMLnfd-XDyHnwG55kuV3G2BMKMqAU8aSjMIBGUOucpowxg-_Z0kBuByRkxCWjEkuGTsmIy5k_M3SMbmZN7btPrB2RT2121D1jelc20xdM33yxQbD1dS6gEXAU3JUFXXAs_07Ie-P87fZM128Pr3MHhbUiBw6KqyVMi8TNCXYqpRMCKWwUBJjkwwKq2JVW0GelVkKgKkAI6UCYXLMuTBiQq6H3LVvP3sMnV65YLCuiwbbPmiIeUoIwbKIXv5Bl23vm9hOQ5okCXAleaRgoIxvQ_BY6bV3q8JvNTC9E6kHkTqK1DuR8cSEXOyT-3KF9nfjx1wE7gcAo4qNQ6-DcdgYtM6j6bRt3T_xX2qgfnk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1544412962</pqid></control><display><type>article</type><title>Endothelial dysfunction in Graves' disease</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Popławska-Kita, A ; Szelachowska, M ; Modzelewska, A ; Siewko, K ; Dzięcioł, J ; Klimiuk, PA ; Górska, M</creator><creatorcontrib>Popławska-Kita, A ; Szelachowska, M ; Modzelewska, A ; Siewko, K ; Dzięcioł, J ; Klimiuk, PA ; Górska, M</creatorcontrib><description><![CDATA[Graves' disease (GD) is an organ-specific autoimmune thyroid disease, characterized by hyperthyroidism due to excessive production of thyroid hormone induced by thyrotropin receptor-specific stimulatory autoantibodies. In this study, we determined serum levels of the soluble forms of ICAM-1, VCAM-1, vWF, IL-6, IL-12, IL-18, fibrinogen and CRP in patients with subclinical (SH) and overt hyperthyroidism (OH) caused by GD to elucidate a possible role of those parameters as markers of endothelium dysfunction (ED). The study included 96 patients: 52 with GD and 44 euthyroid controls, divided into 3 groups according to their thyroid function tests: SH, OH and controls (CG). The values of IL-6, IL-12 and IL-18 were significantly higher in GD than in CG patients (p < 0.0001, p < 0.0001; p < 0.00001, respectively). Significant difference of sVCAM-1 values were found in the patients with GD compared to CG (p < 0.0001). Patients with GD had significantly higher levels of PAI-1 (p < 0.00001), vWF (p < 0.0001), fibrinogen (p < 0.0001) in comparison to CG. In patients with OH, we observed statistically higher values of fibrinogen compared to SH group (p < 0.05). There were no significant differences in serum concentration of other study parameters in patients with SH compared to the OH. ED occurs during subclinical and overt hyperthyroidism causing decreased fibrinolytic activity, hypercoagulability and increased levels of IL-6, Il-12 and IL-18. These results support the notion that serum cytokines could be used as a marker of GD activity. Results of this study support the opinion that GD might require treatment as early as in the phase of SH.]]></description><identifier>ISSN: 1896-1126</identifier><identifier>EISSN: 1898-4002</identifier><identifier>DOI: 10.2478/v10039-012-0047-1</identifier><identifier>PMID: 23612675</identifier><language>eng</language><publisher>Netherlands: Elsevier Urban &amp; Partner Sp. z o.o</publisher><subject>Adult ; Biomarkers - blood ; Blood Coagulation ; C-Reactive Protein - metabolism ; endothelium ; Endothelium, Vascular - metabolism ; Endothelium, Vascular - physiopathology ; Female ; Fibrinogen - metabolism ; Fibrinolysis ; Graves Disease - blood ; Graves Disease - complications ; Graves' disease ; Humans ; hyperthyroidism ; Hyperthyroidism - blood ; Hyperthyroidism - etiology ; Intercellular Adhesion Molecule-1 - blood ; Interleukin-12 - blood ; Interleukin-18 - blood ; Interleukin-6 - blood ; Male ; Middle Aged ; Thyroid Function Tests ; Vascular Cell Adhesion Molecule-1 - blood ; von Willebrand Factor - metabolism</subject><ispartof>Advances in medical sciences, 2013, Vol.58 (1), p.31-37</ispartof><rights>2013 Medical University of Bialystok</rights><rights>Copyright De Gruyter Open Sp. z o.o. 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-3dd668b4ecb1dfb603399ea96e11271ad9047df187b7511e531c66913c8e823c3</citedby><cites>FETCH-LOGICAL-c381t-3dd668b4ecb1dfb603399ea96e11271ad9047df187b7511e531c66913c8e823c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23612675$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Popławska-Kita, A</creatorcontrib><creatorcontrib>Szelachowska, M</creatorcontrib><creatorcontrib>Modzelewska, A</creatorcontrib><creatorcontrib>Siewko, K</creatorcontrib><creatorcontrib>Dzięcioł, J</creatorcontrib><creatorcontrib>Klimiuk, PA</creatorcontrib><creatorcontrib>Górska, M</creatorcontrib><title>Endothelial dysfunction in Graves' disease</title><title>Advances in medical sciences</title><addtitle>Adv Med Sci</addtitle><description><![CDATA[Graves' disease (GD) is an organ-specific autoimmune thyroid disease, characterized by hyperthyroidism due to excessive production of thyroid hormone induced by thyrotropin receptor-specific stimulatory autoantibodies. In this study, we determined serum levels of the soluble forms of ICAM-1, VCAM-1, vWF, IL-6, IL-12, IL-18, fibrinogen and CRP in patients with subclinical (SH) and overt hyperthyroidism (OH) caused by GD to elucidate a possible role of those parameters as markers of endothelium dysfunction (ED). The study included 96 patients: 52 with GD and 44 euthyroid controls, divided into 3 groups according to their thyroid function tests: SH, OH and controls (CG). The values of IL-6, IL-12 and IL-18 were significantly higher in GD than in CG patients (p < 0.0001, p < 0.0001; p < 0.00001, respectively). Significant difference of sVCAM-1 values were found in the patients with GD compared to CG (p < 0.0001). Patients with GD had significantly higher levels of PAI-1 (p < 0.00001), vWF (p < 0.0001), fibrinogen (p < 0.0001) in comparison to CG. In patients with OH, we observed statistically higher values of fibrinogen compared to SH group (p < 0.05). There were no significant differences in serum concentration of other study parameters in patients with SH compared to the OH. ED occurs during subclinical and overt hyperthyroidism causing decreased fibrinolytic activity, hypercoagulability and increased levels of IL-6, Il-12 and IL-18. These results support the notion that serum cytokines could be used as a marker of GD activity. Results of this study support the opinion that GD might require treatment as early as in the phase of SH.]]></description><subject>Adult</subject><subject>Biomarkers - blood</subject><subject>Blood Coagulation</subject><subject>C-Reactive Protein - metabolism</subject><subject>endothelium</subject><subject>Endothelium, Vascular - metabolism</subject><subject>Endothelium, Vascular - physiopathology</subject><subject>Female</subject><subject>Fibrinogen - metabolism</subject><subject>Fibrinolysis</subject><subject>Graves Disease - blood</subject><subject>Graves Disease - complications</subject><subject>Graves' disease</subject><subject>Humans</subject><subject>hyperthyroidism</subject><subject>Hyperthyroidism - blood</subject><subject>Hyperthyroidism - etiology</subject><subject>Intercellular Adhesion Molecule-1 - blood</subject><subject>Interleukin-12 - blood</subject><subject>Interleukin-18 - blood</subject><subject>Interleukin-6 - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Thyroid Function Tests</subject><subject>Vascular Cell Adhesion Molecule-1 - blood</subject><subject>von Willebrand Factor - metabolism</subject><issn>1896-1126</issn><issn>1898-4002</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp9kM9LwzAUx4Mobk7_AC8y8KAI0bykTRs8yZg_YOBFz6FNXjGja2fSDvbfm9npwYOnPMLnfd-XDyHnwG55kuV3G2BMKMqAU8aSjMIBGUOucpowxg-_Z0kBuByRkxCWjEkuGTsmIy5k_M3SMbmZN7btPrB2RT2121D1jelc20xdM33yxQbD1dS6gEXAU3JUFXXAs_07Ie-P87fZM128Pr3MHhbUiBw6KqyVMi8TNCXYqpRMCKWwUBJjkwwKq2JVW0GelVkKgKkAI6UCYXLMuTBiQq6H3LVvP3sMnV65YLCuiwbbPmiIeUoIwbKIXv5Bl23vm9hOQ5okCXAleaRgoIxvQ_BY6bV3q8JvNTC9E6kHkTqK1DuR8cSEXOyT-3KF9nfjx1wE7gcAo4qNQ6-DcdgYtM6j6bRt3T_xX2qgfnk</recordid><startdate>2013</startdate><enddate>2013</enddate><creator>Popławska-Kita, A</creator><creator>Szelachowska, M</creator><creator>Modzelewska, A</creator><creator>Siewko, K</creator><creator>Dzięcioł, J</creator><creator>Klimiuk, PA</creator><creator>Górska, M</creator><general>Elsevier Urban &amp; Partner Sp. z o.o</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BYOGL</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>2013</creationdate><title>Endothelial dysfunction in Graves' disease</title><author>Popławska-Kita, A ; Szelachowska, M ; Modzelewska, A ; Siewko, K ; Dzięcioł, J ; Klimiuk, PA ; Górska, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-3dd668b4ecb1dfb603399ea96e11271ad9047df187b7511e531c66913c8e823c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Biomarkers - blood</topic><topic>Blood Coagulation</topic><topic>C-Reactive Protein - metabolism</topic><topic>endothelium</topic><topic>Endothelium, Vascular - metabolism</topic><topic>Endothelium, Vascular - physiopathology</topic><topic>Female</topic><topic>Fibrinogen - metabolism</topic><topic>Fibrinolysis</topic><topic>Graves Disease - blood</topic><topic>Graves Disease - complications</topic><topic>Graves' disease</topic><topic>Humans</topic><topic>hyperthyroidism</topic><topic>Hyperthyroidism - blood</topic><topic>Hyperthyroidism - etiology</topic><topic>Intercellular Adhesion Molecule-1 - blood</topic><topic>Interleukin-12 - blood</topic><topic>Interleukin-18 - blood</topic><topic>Interleukin-6 - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Thyroid Function Tests</topic><topic>Vascular Cell Adhesion Molecule-1 - blood</topic><topic>von Willebrand Factor - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Popławska-Kita, A</creatorcontrib><creatorcontrib>Szelachowska, M</creatorcontrib><creatorcontrib>Modzelewska, A</creatorcontrib><creatorcontrib>Siewko, K</creatorcontrib><creatorcontrib>Dzięcioł, J</creatorcontrib><creatorcontrib>Klimiuk, PA</creatorcontrib><creatorcontrib>Górska, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>East Europe, Central Europe Database</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Advances in medical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Popławska-Kita, A</au><au>Szelachowska, M</au><au>Modzelewska, A</au><au>Siewko, K</au><au>Dzięcioł, J</au><au>Klimiuk, PA</au><au>Górska, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Endothelial dysfunction in Graves' disease</atitle><jtitle>Advances in medical sciences</jtitle><addtitle>Adv Med Sci</addtitle><date>2013</date><risdate>2013</risdate><volume>58</volume><issue>1</issue><spage>31</spage><epage>37</epage><pages>31-37</pages><issn>1896-1126</issn><eissn>1898-4002</eissn><abstract><![CDATA[Graves' disease (GD) is an organ-specific autoimmune thyroid disease, characterized by hyperthyroidism due to excessive production of thyroid hormone induced by thyrotropin receptor-specific stimulatory autoantibodies. In this study, we determined serum levels of the soluble forms of ICAM-1, VCAM-1, vWF, IL-6, IL-12, IL-18, fibrinogen and CRP in patients with subclinical (SH) and overt hyperthyroidism (OH) caused by GD to elucidate a possible role of those parameters as markers of endothelium dysfunction (ED). The study included 96 patients: 52 with GD and 44 euthyroid controls, divided into 3 groups according to their thyroid function tests: SH, OH and controls (CG). The values of IL-6, IL-12 and IL-18 were significantly higher in GD than in CG patients (p < 0.0001, p < 0.0001; p < 0.00001, respectively). Significant difference of sVCAM-1 values were found in the patients with GD compared to CG (p < 0.0001). Patients with GD had significantly higher levels of PAI-1 (p < 0.00001), vWF (p < 0.0001), fibrinogen (p < 0.0001) in comparison to CG. In patients with OH, we observed statistically higher values of fibrinogen compared to SH group (p < 0.05). There were no significant differences in serum concentration of other study parameters in patients with SH compared to the OH. ED occurs during subclinical and overt hyperthyroidism causing decreased fibrinolytic activity, hypercoagulability and increased levels of IL-6, Il-12 and IL-18. These results support the notion that serum cytokines could be used as a marker of GD activity. Results of this study support the opinion that GD might require treatment as early as in the phase of SH.]]></abstract><cop>Netherlands</cop><pub>Elsevier Urban &amp; Partner Sp. z o.o</pub><pmid>23612675</pmid><doi>10.2478/v10039-012-0047-1</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1896-1126
ispartof Advances in medical sciences, 2013, Vol.58 (1), p.31-37
issn 1896-1126
1898-4002
language eng
recordid cdi_proquest_miscellaneous_1399933307
source ScienceDirect Freedom Collection 2022-2024
subjects Adult
Biomarkers - blood
Blood Coagulation
C-Reactive Protein - metabolism
endothelium
Endothelium, Vascular - metabolism
Endothelium, Vascular - physiopathology
Female
Fibrinogen - metabolism
Fibrinolysis
Graves Disease - blood
Graves Disease - complications
Graves' disease
Humans
hyperthyroidism
Hyperthyroidism - blood
Hyperthyroidism - etiology
Intercellular Adhesion Molecule-1 - blood
Interleukin-12 - blood
Interleukin-18 - blood
Interleukin-6 - blood
Male
Middle Aged
Thyroid Function Tests
Vascular Cell Adhesion Molecule-1 - blood
von Willebrand Factor - metabolism
title Endothelial dysfunction in Graves' disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T13%3A11%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Endothelial%20dysfunction%20in%20Graves'%20disease&rft.jtitle=Advances%20in%20medical%20sciences&rft.au=Pop%C5%82awska-Kita,%20A&rft.date=2013&rft.volume=58&rft.issue=1&rft.spage=31&rft.epage=37&rft.pages=31-37&rft.issn=1896-1126&rft.eissn=1898-4002&rft_id=info:doi/10.2478/v10039-012-0047-1&rft_dat=%3Cproquest_cross%3E3369101961%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c381t-3dd668b4ecb1dfb603399ea96e11271ad9047df187b7511e531c66913c8e823c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1544412962&rft_id=info:pmid/23612675&rfr_iscdi=true